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Abstract
Gay, bisexual, and other men who have sex with men (MSM) are disproportionately affected by 
HIV but few MSM-specific evidence-based interventions (EBIs) have been identified for this 
vulnerable group. We conducted a systematic review to identify reasons for the small number of 
EBIs for MSM. We also compared study, intervention and sample characteristics of EBIs vs. non-
EBIs to better understand the challenges of demonstrating efficacy evidence. Thirty-three MSM-
specific studies were evaluated: Nine (27%) were considered EBIs while 24 (73%) were non-EBIs. 
Non-EBIs had multiple methodological limitations; the most common was not finding a 
significant positive effect. Compared to EBIs, non-EBIs were less likely to use peer intervention 
deliverers, include sexual communication in their interventions, and intervene at the community 
level. Incorporating characteristics associated with EBIs may strengthen behavioral interventions 
for MSM. More EBIs are needed for substance-using MSM, MSM of color, MSM residing in the 
South and MSM in couples.
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INTRODUCTION
In the fourth decade of the HIV/AIDS pandemic, gay, bisexual, and other men who have sex 
with men (MSM) continue to be the most vulnerable group for HIV infection in the U.S. 
MSM comprise 51% of the estimated 1.2 million people living with HIV in the U.S. [1] 
Although MSM comprise ~2% of the U.S. population [2], they account for 61% of all new 
HIV infections [3]. The rate of new HIV diagnoses for MSM is at least 44 times that of other 
men [2] and since the year 2000, MSM are the only group where new infections are rising 
annually [4]. Given these recent and alarming trends, it is critical to examine current HIV 
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prevention approaches to better understand how efforts can be improved to help reverse the 
trends. One area that may benefit from this kind of examination is behavioral interventions 
for MSM.
Behavioral Interventions and HIV Prevention
Behavioral interventions dominated early HIV prevention efforts when effective biomedical 
and treatment options were not yet available and reducing risky behaviors was the best 
option [5, 6]. For MSM and other HIV risk groups, the majority of risk reduction behavioral 
interventions have been delivered to individuals 1-on-1 or in small groups, using cognitive-
behavioral approaches [7]. These approaches attempt to change an individual’s beliefs, 
attitudes, and behaviors to reduce HIV risk. Community-level behavioral interventions using 
popular opinion leaders, diffusion of innovation theory, or community mobilization have 
also been conducted [8, 9]. Behavioral interventions have demonstrated evidence of 
reducing risk behavior across different populations [10], including MSM [11–15], but have 
not shown substantial evidence for reducing biomedical outcomes such as STI or HIV 
infection [16, 17]. Like any single prevention approach, behavioral interventions may be 
insufficient as a stand-alone prevention strategy for producing an impactful and sustainable 
reduction in HIV infection [18].
With advances in HIV treatment and biomedical approaches to HIV prevention, and a 
growing awareness of the importance of structural and social determinants of health, HIV 
prevention is moving towards a high-impact, multi-level approach. This high-impact 
approach uses a mixture of different types and levels of interventions that is evidence-
informed, cost-effective, and tailored for a particular community in order to make the 
greatest sustained impact on reducing new HIV infections [5]. Analogous to using 
antiretroviral therapy (ART) or a combination of different classes of HIV drugs to treat a 
person living with HIV, a high-impact prevention approach is based on the HIV 
epidemiological profile of a community and uses the most effective combination of 
biomedical, structural, and behavioral strategies [18]. Biomedical interventions such as ART 
and pre-exposure prophylaxis (PrEP) [19], in particular, have generated much excitement 
and reflect the increasing “medicalization” of HIV prevention. However, there are many 
behavioral and social implications of biomedical interventions that must be addressed for 
these interventions to be effective [20]. For example, increased risk behavior can outweigh 
the effectiveness of ART in reducing HIV incidence by as much as 30% [21] and the 
outcomes of recent PrEP trials highlight the importance of adherence behaviors in obtaining 
the most impact from PrEP [19]. Furthermore, the continued importance of efficacious 
behavioral interventions is underscored in the National HIV/AIDS Strategy (NHAS) that 
prioritizes scalable behavioral interventions for decreasing sexual and drug-use risk 
behaviors of MSM and other HIV vulnerable groups [22]. Given this emphasis on high-
impact prevention in NHAS, the need for evidence-based behavioral interventions for MSM 
remains a crucial piece of a high-impact approach to HIV prevention among MSM.
Evidence-based HIV Behavioral Interventions
In 1996, the Centers for Disease Control and Prevention (CDC) created the Prevention 
Research Synthesis (PRS) team to systematically review and summarize HIV behavioral 
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intervention research literature with the goal of translating scientific evidence from the 
research literature into evidence-based HIV prevention recommendations [23]. PRS 
developed efficacy criteria to assess a study’s design, quality of study implementation and 
analysis, and strength of findings through multiple consultations with internal and external 
HIV prevention researchers and methodology experts (http://www.cdc.gov/hiv/topics/
research/prs/efficacy_criteria.htm). Mirroring the criteria used by other projects such as the 
Community Guide and Grades of Recommendation Assessment, Development and 
Evaluation (GRADE), PRS efficacy criteria focus on internal validity “to ensure a 
reasonable level of confidence that the observed changes can be attributed to the 
intervention” [23]. Interventions meeting PRS efficacy criteria are identified as evidence-
based behavioral interventions (EBIs).
Although U.S. MSM are disproportionately affected by HIV, relatively few MSM-specific 
EBIs have been identified. Out of 74 US-based EBIs PRS identified as of May 2011 in the 
CDC’s Compendium of Evidence-Based Behavioral Interventions (http://www.cdc.gov/
hivtopics/research/prs/rr_chapter.htm), only 14 EBIs were listed for MSM. Of these, only 8, 
or 11%, of 74 were specifically designed for MSM. Considering that MSM comprise the 
majority of new HIV cases, it is puzzling that only 11% of the PRS-identified EBIs have 
explicitly focused on this vulnerable population. Is the small number of EBIs reflective of 
few behavioral HIV prevention interventions having been specifically designed for MSM or 
is it because many interventions have been developed for MSM but few have demonstrated 
sufficient evidence of efficacy? To answer these questions, we conducted a qualitative 
systematic review of behavioral HIV prevention interventions specifically designed for 
MSM. Our objectives were to (1) identify the number of behavioral HIV prevention 
interventions specifically designed for MSM, (2) understand the challenges of demonstrating 
efficacy for MSM behavioral interventions by examining the study design, implementation, 
analysis, and strength of findings of interventions that did not meet efficacy criteria (non-
EBIs), and (3) compare study, intervention and sample characteristics of non-EBIs with 
EBIs. We believed a better understanding of these issues will facilitate the development of 
efficacious behavioral interventions for MSM.
METHODS
Search Strategy
We searched the CDC’s PRS database for evaluations of MSM-specific behavioral 
interventions in January 2010. Another search was conducted in May 2011 to locate studies 
not captured in the initial search. The PRS database is annually updated by 2 research 
librarians who conduct systematic searches of several bibliographic databases including 
CINAHL, EMBASE, MEDLINE, PsycINFO, and Sociological Abstracts [24]. The last 
electronic systematic update of the PRS database was February 2011 for articles indexed in 
searched databases by December 2010. Quarterly hand searches of 38 crucial HIV/AIDS 
journals, reference lists checks, and contacting key authors are also implemented to 
supplement electronic database searches. We also examined online registries (i.e., Cochrane 
Library, ISI Web of Knowledge, RePORTER, and CRD databases) for any related research. 
The full search strategy for each database is available from the authors [24].
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Eligible studies for this review were: (1) behavioral interventions to reduce HIV infection 
and transmission: (2) specifically designed for MSM; (3) conducted in the U.S.; (4) tested in 
randomized controlled trials with a comparison arm; (5) measured HIV behavioral or 
biological outcomes (e.g., condom use, number of sex partners, sexually transmitted 
infections, HIV infection); (6) and published between January 1988 and December 2010. We 
excluded studies not published in peer reviewed journals, studies not specifically designed 
for MSM even though they included a majority of MSM in their samples, and pilot studies if 
the full-scale efficacy trials were eligible. Adaptations of interventions were included but 
replications were excluded to avoid overweighting characteristics from previous 
interventions already included in the review.
Data Extraction and Analysis
Two trained coders independently coded eligible intervention studies, entered codes in the 
PRS database, and met to reconcile all discrepancies. If a study did not report critical 
information needed to determine intervention efficacy, we contacted the primary study 
investigator to obtain missing information or additional clarification. The final efficacy 
determination for each study was reached by PRS team consensus.
For each eligible study, we coded study characteristics (e.g., study date, location, eligibility), 
intervention content (e.g., behavioral determinants of risks), intervention characteristics 
(e.g., time span or duration of the intervention measured in weeks, number of sessions, level 
of delivery), and participant characteristics (e.g., racial/ethnic background, HIV status) on 
standardized coding forms. Following the standardized efficacy review procedure (http://
www.cdc.gov/hiv/topics/research/prs/efficacy_criteria.htm), we evaluated research design, 
study implementation, analysis, and strength of findings of each eligible study against 
efficacy criteria established as good evidence for either individual- and group-level 
interventions (http://www.cdc.gov/hiv/topics/research/prs/efficacy good-evidence.htm) or 
community-level interventions (http://www.cdc.gov/hiv/topics/research/prs/efficacy_good-
evidence_CLIs.htm) An SPSS data file of final codes was generated from the PRS database.
Methodological and Analytic Approaches
Eligible interventions were classified into four categories based on the efficacy review:
• EBIs that met all efficacy criteria;
• “rigorous non-EBIs” that met all efficacy criteria except for a significant positive 
finding;
• “positive non-EBIs” that reported a significant positive finding but did not meet 
at least one other PRS criterion; and
• “other non-EBIs” that did not have a significant positive finding and did not meet 
at least one other PRS criterion.
Using SPSS Version 18, we examined study, intervention, and participant characteristics 
with descriptive statistics (e.g., medians, frequencies). We excluded community-level 
interventions when calculating median number of intervention sessions, session duration 
(length of an individual session measured in hours), intervention time spans (the duration of 
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the intervention measured in weeks), and total intervention hours (number of sessions 
multiplied by session duration) because intervention exposure at the community level is 
likely to differ at the individual level and estimates for these characteristics were not 
reported. To examine differences in study characteristics, intervention content, and 
participant characteristics between EBIs and non-EBIs, we conducted Fisher’s exact tests 
and non-parametric independent samples median tests. We compared EBIs with all non-
EBIs as a whole and with each non-EBI subgroup. We also compared studies that did not 
find a significant positive effect (a combined group of rigorous and other non-EBIs) to EBIs 
to identify potential characteristics that may contribute to a significant positive effect.
RESULTS
Literature Search
PRS evaluated 353 US-based behavioral interventions that were conducted between January 
1988 and December 2010 (Figure 1). Out of this total, 47 interventions (13%) were 
specifically tailored for MSM or tested with majority of MSM in their samples. Of these, 14 
were not eligible: 11 were interventions designed for persons living with HIV and had 
majority of MSM (over 50%) in their samples [25–35]. These studies were ineligible for the 
review because they were not specifically designed for MSM. The remaining three ineligible 
interventions included a replication [36], unpublished manuscript [37], and a pilot study 
whose full-scale trial was included in the review [38]. A total of 33 interventions met review 
eligibility criteria and were examined using PRS efficacy criteria. Descriptive characteristics 
of the studies are presented in Table 1.
Overall Characteristics of MSM Behavioral Interventions
Introduction of ART—Among the 33 studies we examined, 11 (33%) were conducted 
before ART or prior to 1996 while 22 studies (67%) were conducted after ART. The 
majority (82%) of pre-ART studies were conducted in small group settings while the 
remaining studies were implemented as community-level interventions (18%). No 
individual-level interventions for MSM were conducted in this time period. In the post-ART 
period, half of the interventions were conducted as individual-level interventions while the 
other half were delivered in small groups. No post-ART studies were conducted as 
community-level interventions.
Intervention Sites—The majority of studies (n=26, 79%) were single-site studies, while 4 
(12%) were multi-site studies. The 3 remaining studies were conducted nationwide using the 
internet [39, 40] and telephone [41]. The most commonly reported intervention sites were 
urban settings where higher proportions of MSM congregate: New York City, San Francisco, 
Los Angeles, and Seattle. Regionally, most interventions were conducted in the West, 
followed by the Northeast. The fewest interventions were conducted in the South.
Targeted MSM Subpopulations—In terms of MSM subpopulations, 6 studies (18%) 
exclusively focused on MSM of color and 7 studies (21%) intervened with substance-using 
MSM. Nine (27%) studies concentrated on HIV-positive MSM and 6 (18%) targeted HIV-
negative MSM; the majority of studies (n=18, 55%) did not include HIV status as an 
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eligibility criterion. A higher percent of MSM studies conducted post-ART focused on high-
risk MSM when compared to the pre-ART period: 36% vs. 9% focused on HIV-positive 
MSM and 27% vs. 9% focused on substance-using MSM respectively.
Intervention Design—Approximately 42% of the studies used wait-list groups as 
comparisons (n=14) while 11 studies (33%) used HIV-related comparison groups and eight 
(24%) used non-HIV related comparison groups. The majority of interventions were 
conducted in small groups (n=20, 61%). Eleven (33%) were individual- level interventions 
while two (6%) were community-level interventions. No interventions focused on couples. 
Nine (27%) studies reported power analysis results [42–50] (not shown in a table).
PRS Categories of Interventions
Of the 33 eligible MSM intervention studies, 9 (27%) met all PRS efficacy criteria and are 
considered EBIs [8, 9, 43–45, 50, 51–53] while the remaining 24 (73%) interventions that 
did not meet PRS efficacy criteria were identified as non-EBIs [39, 41, 42, 46–49, 54–68]. 
The most commonly identified failed criteria among the 24 non-EBIs were not finding 
significant positive intervention effects on a relevant behavioral or biological outcome 
(n=13, 39%) [42, 46, 47, 49, 54, 58–60, 63–66, 68], having follow-up assessments less than 
1 month after the intervention (n=6, 18%) [41, 47, 55, 56, 62, 66], having analytic sample 
sizes less than 40 study participants per arm, (n=5, 15%) [42, 48, 55, 64, 65] having less 
than a 60% retention rate of study participants per arm (n=3, 9%) [39, 57, 65]. In addition, 
several other limitations such as substantial missing data, significant negative findings, data 
analysis issues or inconsistent findings were problems for 6 interventions (18%) [40, 47, 59, 
61, 63, 64].
The 24 interventions that did not meet at least 1 PRS efficacy criterion fell into 3 non-EBI 
groups. Seven interventions (21%) met all efficacy criteria except for a significant positive 
finding and were categorized as rigorous non-EBIs [46, 49, 54, 58, 60, 63, 68]. Eleven 
interventions (33%) reported a significant positive finding on a relevant behavioral or 
biological outcome but did not meet at least one other PRS criterion and were classified as 
positive non-EBIs [39–41, 48, 55–57, 61, 62, 67, 69]. Finally, the remaining 6 (18%) 
interventions did not have a significant positive finding on a relevant behavioral or biological 
outcome and did not meet at least one other PRS criterion [42, 47, 59, 64–66]. These 
interventions were identified as other non-EBIs.
Non-EBIs as a whole significantly differed from EBIs on study and intervention 
characteristics (Table 2). Non-EBIs were significantly more likely to exclusively focus on 
HIV-negative MSM and significantly less likely to be pilot tested, delivered by peers, and 
include intervention content on sexual communication (e.g., sexual negotiation) compared to 
EBIs. No EBIs included substance use as an eligibility criterion. Over half of the EBIs were 
conducted in the West and most EBIs used wait-list comparison groups. EBIs reported the 
most variety in terms of intervention delivery level (e.g., individual, small group, 
community) whereas the majority of non-EBIs were conducted in small groups. Excluding 
the 2 community-level interventions, EBIs reported the shortest median time span for an 
intervention and lowest median total number of hours allocated for an intervention.
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Rigorous Non-EBIs—Seven studies that met all PRS efficacy criteria with the exception 
of finding a significant positive effect were classified as rigorous non-EBIs. All rigorous 
non-EBIs were conducted post-ART. When compared to EBIs, rigorous non-EBIs were 
significantly more likely to include substance use as an eligibility criterion and report study 
participants with a high school education or less. Also, rigorous non-EBIs were significantly 
less likely to be conducted in MSM settings and include sexual communication as part of the 
intervention in contrast to EBIs (Table 2).
Positive non-EBIs—Although these 11 studies found a significant positive effect, they did 
not meet other efficacy criteria. Having only an immediate follow-up assessment (n=4, 36%) 
[41, 55, 56, 62] was the most common reason for not meeting efficacy criteria. Other 
common reasons included having analytic sample sizes less than 40 per arm (n=2, 18%) [48, 
55] and having less than 60% retention in at least 1 study arm (n=2, 18%) [39, 57]. The 
remaining interventions had other study limitations such as reported contradictory findings, 
substantial missing data, significant negative findings or re-assigned participants from the 
intervention arm to the control arm or excluded participants who missed interventions 
sessions from the analyses (n=4, 36%) [40, 61, 67, 69]. As shown in Table 1, the internet- 
and telephone-based interventions were classified as positive non-EBIs. Although not 
statistically significant, positive non-EBIs reported the lowest median number of 
intervention sessions, lowest median percent of blacks, and highest median percent of whites 
in their samples compared to EBIs, rigorous, and other non EBIs. They also reported the 
lowest median percent of study participants with a high school education or less. When 
positive non-EBIs were compared to EBIs, no statistically significant differences in study 
characteristics, intervention content, or participant characteristics emerged.
Other non-EBIs—Besides lacking a significant positive effect for a relevant behavioral or 
biological outcome, these 6 studies also did not meet at least one other efficacy criterion. For 
other non-EBIs, reasons for not meeting PRS criteria were having analytic sample sizes less 
than 40 per arm (n=3, 50%) [42, 64, 65], having follow-up assessments less than 1 month 
(n=2, 33%) [47, 66], having significant negative findings (n=2, 33%) [47, 64] and biased 
allocation of participants to intervention and comparison arms [59]. Other non-EBIs 
reported the highest percent of interventions conducted in groups (n=5, 83%) compared to 
EBIs, rigorous non-EBIs, and positive non-EBIs. Other non-EBIs were also significantly 
less likely to pilot test interventions compared to EBIs (Table 2).
Rigorous & Other non-EBIs Combined—When we combined rigorous and other non-
EBIs (n=13) or studies that did not find a significant positive intervention effect and 
compared this group with EBIs (not shown), we found similar results from previous 
comparisons. For example, rigorous and other non-EBIs combined were significantly more 
likely to include substance use (33% vs. 0, p = 0.05) and exclusively focus on HIV negative 
men (44% vs. 0, p=0.02) as eligibility criteria compared to EBIs. In addition, the combined 
group of rigorous and other non-EBIs was significantly less likely to be pilot tested (8 vs. 
67%, p =0.01) and include sexual communication as part of the intervention (31 vs. 89%, p 
= 0.01) in contrast to EBIs. Finally, rigorous and other non-EBIs combined were more likely 
to use a non-HIV related comparison group in contrast to EBIs (46% vs. 0, p = 0.05).
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DISCUSSION
Of the 353 funded behavioral intervention studies evaluated by PRS since 1996, only 13%, 
or 47, exclusively focused on MSM. Similarly, of the 74 EBIs identified by PRS, only 8 
(11%) were specifically designed for MSM. These percentages are much smaller than would 
be expected given the cumulative impact of HIV on MSM. The similarity of proportions 
between studies funded exclusively for MSM (13%) and those found to be efficacious (11%) 
suggests that the low number of EBIs for MSM is more attributable to misaligned funding 
priorities than to particular issues with interventions for MSM. Another possible explanation 
may be that few MSM-focused intervention studies are being proposed. Although 24 (73%) 
of the 33 MSM-specific interventions included in this review were determined by PRS to be 
non-efficacious, they offer important lessons that can guide further research.
Lessons Learned from Non-efficacious MSM-specific Interventions
Not finding a significant positive effect—Findings from this study suggest that it may 
be difficult to demonstrate significant positive changes in sexual behavior with MSM who 
experience substance use issues. MSM with substance use issues often experience other 
psychosocial health problems like depression and partner violence [70]. From a “syndemics” 
perspective, it may be difficult for MSM who experience multiple interconnected issues such 
as substance use, depression, a history of sexual child abuse or partner violence to change 
sexual risk behaviors [46, 70, 71]. Efficacious interventions for substance-using MSM who 
experience multiple vulnerabilities may require a comprehensive approach that addresses 
substance use specifically (e.g., methadone treatment, individual therapy, contingency 
management) [72], accounts for various MSM populations (e.g., MSM who use injection 
drugs, MSM who use recreational drugs on the weekends), and targets venues combining 
sexual activity and substance use [71]. Addressing interconnected syndemic factors (e.g., 
treating depression, counseling for childhood sexual abuse or partner violence) while using 
biomedical strategies (e.g., PrEP and/or PEP) and structural interventions (e.g., decreasing 
stigma and discrimination related to being gay) should also be a part of this comprehensive 
approach[72, 73].
For substance-using and other high-risk MSM, it may be more efficacious to use individual-
level interventions rather than group-level interventions. In our review, a larger proportion of 
non-EBIs (71%) used groups to deliver the intervention compared to EBIs (33%). Delivering 
interventions to high-risk MSM in a group setting may have some unintended outcomes. 
Some evidence indicates that small group formats may actually reinforce and sustain risk 
behaviors for high-risk MSM through meeting similarly or more-risky men [14]. An 
advantage of one-on-one interventions such as EXPLORE is that they can be tailored to 
meet a high-risk individual’s specific prevention needs [74]. However, to have maximum 
impact, it may be necessary to use a combination approach that includes other kinds of 
strategies such as biomedical or structural interventions to reinforce engaging in safer 
behaviors for high-risk MSM.
Another factor that may contribute to interventions not finding effects is the type of 
comparison group. In our review, interventions that did not find significant positive effects 
were more likely to use a non-HIV comparison group (i.e., served as attention control) while 
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EBIs were more likely to use wait-list or HIV-related comparison groups. In addition, the 
number of MSM studies that used wait-list controls decreased over time while more recent 
studies were more likely to use HIV-related comparison groups as demand controls. These 
findings suggest that using non-HIV specific comparison groups that focus on general health 
promotion or stress reduction may encourage comparison participants to think about and 
possibly make changes in sexual health behaviors [39, 68]. However, using wait-list and 
HIV-related comparison groups also have their disadvantages. Some researchers argue for 
using control groups with minimal or no treatment when conducting rigorous intervention 
evaluations [58], but the problem with this approach is that it does not control for attention 
or demand effects. Also, temporarily withholding interventions from individuals and 
communities severely impacted by HIV may be perceived as unethical. A potential 
disadvantage of using HIV-related comparison groups is the use of enhanced or exceptional 
HIV prevention programs or diluted versions of the new intervention as comparison groups 
that may greatly reduce the ability to detect effects [16]. Researchers should consider the 
advantages and disadvantages of using each type of comparison group and address issues 
related to controlling for attention and demand effects. Using a standardized comparison arm 
that the HIV prevention field could agree upon as a prevention standard for MSM can 
facilitate comparing intervention effects across studies.
Sample Sizes and Retention Rates—One of the major reasons why interventions in 
our review did not meet efficacy criteria was not having at least 40 study participants per 
arm at follow-up assessment. Some of the interventions were conducted as small scale pilot 
studies to test feasibility and thus started with small sample sizes at baseline [42, 64]. Other 
interventions suffered from attrition problems [48, 65]. A prior power analysis can help to 
determine the adequate sample size for detecting an intervention effect but only 28% of the 
studies in our review reported power analysis results. More transparent reporting of power 
analyses would facilitate evaluation of evidence. Finally, recruiting and retaining MSM in 
HIV behavioral prevention studies, especially studies with a substance use focus, may be 
more challenging than in the past [75]. The HIV prevention field would greatly benefit from 
comparative research and a compendium of “best practices” specifically focusing on 
recruiting and retaining MSM in intervention studies [75]. Newer recruitment methods such 
as respondent-driven, venue-day-time, and internet sampling show promise [76, 77] but 
more research is needed to evaluate their strengths and limitations.
Follow-up assessments—Having a follow-up assessment at least 1 month post-
intervention was another common criterion that non-EBIs failed to meet in our review. These 
interventions only reported intervention effects immediately after the interventions were 
completed and thus the sustainability of the intervention effects is unclear. Given the 
emphasis on sustainable interventions in NHAS, HIV prevention researchers should consider 
longer follow-up assessments extending past immediate post- intervention to provide 
stronger evidence for sustainable changes in risk-reduction behavior.
Considerations for Future MSM Behavioral Interventions
MSM Inclusion and Focus in Interventions—A few intervention characteristics of 
EBIs that distinguished these interventions from those not meeting efficacy criteria might be 
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helpful to consider when designing future behavioral interventions for MSM. For example, 
involving MSM in the design and implementation of interventions may be important. In our 
review, pilot testing and delivering the intervention through peers were more often 
characteristic of EBIs than non-EBIs. Pilot testing the intervention in the MSM community 
can provide information to improve the intervention. Using peers as intervention deliverers 
may help create an intervention environment that is safe and socially comfortable for MSM.
Researchers should also consider including intervention content on sexual communication, 
as it was associated with efficacious interventions. Other studies have also found sexual 
communication as an important component in behavioral interventions for MSM [11, 13]. 
Sexual negotiation and other communication skills such as HIV disclosure are critical if 
MSM rely on serostatus-based prevention strategies such as serosorting and strategic 
positioning to reduce their HIV risk. Innovative interventions are particularly important to 
help men with sexual negotiation and HIV disclosure skills in public and commercial sex 
environments where silence may be the norm [78]. As technological sites such as websites 
and phone apps become more popular to meet sexual partners among MSM, appropriate 
messages and strategies to enhance sexual communication will need to be developed with 
these new environments in mind.
MSM of color—There was an increase in the number of interventions conducted with 
high-risk MSM post-ART compared to pre-ART, but compared to the number of 
interventions PRS has evaluated, the number of interventions specifically developed for 
MSM of color is relatively few. Developing efficacious behavioral interventions for these 
highly impacted MSM subgroups, especially African American and Latino MSM is urgently 
needed. EBIs and non-EBIs reported similar median percentages for including black, Latino, 
and white MSM in their samples, but only 2 EBIs in our review exclusively focused on 
MSM of color [51, 53]. One was developed for Asian and Pacific Islander MSM and was 
conducted in the pre-ART era, while the other EBI is a group intervention designed for HIV-
negative African Americans. Currently, there are no efficacious behavioral interventions that 
have been specifically developed for Latino MSM or those that exclusively focus on HIV-
positive MSM of color. Researchers should consider addressing the cultural and contextual 
factors that have been associated with risk behavior with MSM of color [79, 80]. 
Acknowledging and addressing the health disparities as well as the economic and social 
inequities confronting MSM of color are also needed as a part of a comprehensive approach 
for reducing HIV in these groups.
HIV Positive MSM—In this review, the percentage of interventions that exclusively 
focused on HIV-positive MSM were not significantly different between EBIs and non-EBIs, 
but EBIs were significantly more likely than non-EBIs to exclusively focus on HIV-negative 
MSM. This finding suggests that it may be challenging to demonstrate significant positive 
effects with HIV-positive MSM compared to HIV-negative MSM. Several efficacious 
behavioral interventions have been developed for HIV-positive persons in general (http://
www.cdc.gov/hiv/topics/research/prs/subset-best-evidence-interventions.htm#link2.6) and a 
large percentage of study participants in these studies were MSM. In our review, however, 
only 2 [50, 52] out of 9 interventions for HIV-positive MSM were efficacious. A factor that 
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may contribute to non-efficacious behavioral interventions for HIV-positive MSM is the 
level of intervention. In this review, the majority of non-EBIs for HIV-positive MSM were 
group-level interventions. Intervening at the individual level reduces sexual risk for HIV-
positive persons in general [81] and may be particularly important for HIV-positive MSM. 
As mentioned earlier, group-level interventions may inadvertently reinforce risky behavior 
for high-risk MSM and have fewer opportunities for specific tailoring that may be important 
for behavior change. Another factor that may explain why we found relatively few 
efficacious behavioral interventions for HIV-positive MSM is the intervention setting or 
where the intervention is delivered. Previous research shows behavioral interventions 
conducted in clinical settings where HIV-positive persons regularly receive medical or social 
services may be more effective in reducing sexual risk than non-clinical settings [81]. Future 
behavioral interventions to reduce sexual risk for HIV-positive MSM should consider 
individual-level interventions and delivering these interventions in settings where other 
services are also available.
Other Gaps—HIV is greatly impacting MSM in the South [82], but we found the fewest 
interventions conducted there in our review. Because many MSM interventions have been 
developed and conducted in the West and Northeast, researchers should consider the cultural 
differences in the South (e.g., being located in the Bible belt) that can make HIV prevention 
more challenging for MSM and other vulnerable populations.
Our review also found that efficacious technology-based behavioral interventions have yet to 
be developed for MSM. Retention in these interventions may be challenging [39, 83] but 
behavioral interventions for MSM using digital media via the Internet, mobile phones, and 
computers have demonstrated the potential for increasing HIV testing [84], increasing HIV 
disclosure [85], and reaching high-risk MSM [86] and rural MSM [87].
Another gap in the MSM intervention literature is the lack of interventions for couples [88]. 
Some evidence indicates that most HIV transmissions occur within primary partner 
relationships [89] and, thus, developing couple-based behavioral interventions for MSM 
should be a priority. A recent pre-posttest design study that evaluated a couple-based 
intervention for methamphetamine-using black MSM found encouraging results for reducing 
sexual risk and illicit drug use [90].
Finally, early interventions that were evaluated as efficacious pre-ART should be replicated 
to determine if they are still efficacious post-ART [91]. It is important to recognize that 
interventions that worked 10 years ago may not be comparably effective today and that they 
should be continually assessed for effectiveness as they are implemented in practice [92].
From Research to Practice
While the identification of EBIs is informative, several more steps are necessary to translate 
scientific knowledge into impactful practice. PRS efficacy criteria currently focus on internal 
validity to ascertain causality between the intervention and behavior change, but scalability, 
sustainability, and cost-effectiveness are additional critical factors to determine which EBIs 
and combinations of EBIs are likely to achieve high-impact outcomes [22]. Emphasizing 
these other qualities reflects the importance of examining an intervention’s external or 
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“viable” validity - or the extent to which the intervention is “practical, affordable, suitable, 
evaluable, and helpful in the real world” [93]. Also, standards for evaluating external validity 
or the capacity for an intervention to generalize to other populations or settings would be 
helpful for effective intervention implementation in affected communities. More 
implementation research about how interventions work in the field and how to maximize 
their reach and impact is also important for facilitating the translation of research into best 
practices.
Limitations
Our study has several limitations that warrant caution when interpreting the results. 
Although we contacted primary investigators to confirm the efficacy evaluation, the coding 
of study and intervention characteristics are based on published reports that may not provide 
complete information about the intervention. While we observed some patterns that may 
explain differences among EBIs and non-EBIs, there are multiple factors that may contribute 
to an intervention’s lack of evidence and it is difficult to disentangle a specific reason or 
combination of reasons. Also, our review focused on original studies; replications were 
excluded from this review. Replications are informative especially when examining 
generalizability, but few were conducted. These issues should be further examined when 
more studies become available in the literature. We excluded interventions that were not 
specifically designed for MSM but had substantial numbers of MSM in their samples (e.g., 
HIV clinic patients). Future studies may want to compare characteristics of interventions 
tailored specifically to MSM with general interventions tested with a majority of MSM in 
their samples. Finally, we did not examine cost data because few original studies provided 
the information.
CONCLUSIONS
In the fourth decade of HIV prevention, behavioral interventions will continue to play an 
important role in HIV prevention efforts for MSM but need to be strengthened to make a 
substantial impact as part of a comprehensive HIV prevention package. They should target 
MSM at the highest risk of transmitting and acquiring HIV and consider the gaps in HIV 
behavioral intervention research for MSM. Behavioral interventions should also focus on 
relevant issues for MSM and include MSM in their design and implementation. In short, 
HIV behavioral interventions will need to continually evolve, as they have throughout the 
epidemic, to help reduce HIV vulnerability for gay, bisexual, and other men who have sex 
with men.
Reference List
1. CDC. CDC Factsheet: HIV and AIDS among gay and bisexual men. Published May 2012 http://
www.cdc.gov/hiv/topics/msm/pdf/msm.pdf. Accessed 1 Feb 2013.
2. Purcell DW, Johnson CH, Lansky A et al. Estimating the Population Size of Men Who Have Sex 
with Men in the United States to Obtain HIV and Syphilis Rates. Open AIDS J 2012;6:98–107. 
[PubMed: 23049658] 
3. Prejean J, Song R, Hernandez A et al. Estimated HIV incidence in the United States, 2006–2009. 
PLoS One 2011;6(8):e17502. [PubMed: 21826193] 
Higa et al. Page 12
AIDS Behav. Author manuscript; available in PMC 2019 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Hall HI, Song R, Rhodes P et al. Estimation of HIV incidence in the United States. JAMA 
2008;300(5):520–529. [PubMed: 18677024] 
5. Hankins CA, de Zalduondo BO. Combination prevention: a deeper understanding of effective HIV 
prevention. AIDS 2010;24(Suppl 4):S70–S80. [PubMed: 21042055] 
6. Mansergh G, Higa D. HIV/AIDS in lesbian, gay, bisexual, and transgender communities In: Hall JC, 
Hall BJ, Cockerell CJ, editors. HIV/AIDS in the Post-HAART Era: Manifestations, Treatment, and 
Epidemiology.Shelton, CT: People’s Medical Publishing House; 2011 709–721.
7. Kelly JA, Kalichman SC. Behavioral research in HIV/AIDS primary and secondary prevention: 
recent advances and future directions. J Consult Clin Psychol 2002;70(3):626–639. [PubMed: 
12090373] 
8. Kegeles SM, Hays RB, Coates TJ. The Mpowerment Project: a community-level HIV prevention 
intervention for young gay men. Am J Public Health 1996;86(8):1129–1136. [PubMed: 8712273] 
9. Kelly JA, St Lawrence JS, Stevenson LY et al. Community AIDS/HIV risk reduction: the effects of 
endorsements by popular people in three cities. Am J Public Health 1992;82(11):1483–1489. 
[PubMed: 1443297] 
10. Noar SM. Behavioral interventions to reduce HIV-related sexual risk behavior: review and 
synthesis of meta-analytic evidence. AIDS Behav 2008;12(3):335–353. [PubMed: 17896176] 
11. Herbst JH, Sherba RT, Crepaz N et al. A meta-analytic review of HIV behavioral interventions for 
reducing sexual risk behavior of men who have sex with men. J Acquir Immune Defic Syndr 
2005;39(2):228–241. [PubMed: 15905741] 
12. Herbst JH, Beeker C, Mathew A et al. The effectiveness of individual-, group-, and community-
level HIV behavioral risk-reduction interventions for adult men who have sex with men: a 
systematic review. Am J Prev Med 2007;32(Suppl 4):S38–S67. [PubMed: 17386336] 
13. Johnson WD, Hedges LV, Ramirez G et al. HIV prevention research for men who have sex with 
men: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2002;30(Suppl 
1):S118–S129. [PubMed: 12107365] 
14. Johnson WD, Holtgrave DR, McClellan WM, Flanders WD, Hill AN, Goodman M. HIV 
intervention research for men who have sex with men: a 7-year update. AIDS Educ Prev 
2005;17(6):568–589. [PubMed: 16398578] 
15. Johnson WD, Diaz RM, Flanders WD et al. Behavioral interventions to reduce risk for sexual 
transmission of HIV among men who have sex with men. Cochrane Database Syst Rev 2008;
(3):CD001230. [PubMed: 18646068] 
16. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: 
challenges in HIV prevention research. AIDS 2010;24(5):621–635. [PubMed: 20179575] 
17. Ross DA. Behavioural interventions to reduce HIV risk: what works? AIDS 2010;24(Suppl 4):S4–
S14. [PubMed: 21042051] 
18. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make 
them work better. Lancet 2008;372(9639):669–684. [PubMed: 18687459] 
19. Grant RM, Lama JR, Anderson PL et al. Preexposure chemoprophylaxis for HIV prevention in 
men who have sex with men. N Engl J Med 2010;363(27):2587–2599. [PubMed: 21091279] 
20. de Wit JB, Aggleton P, Myers T, Crewe M. The rapidly changing paradigm of HIV prevention: 
time to strengthen social and behavioural approaches. Health Educ Res 2011;26(3):381–392. 
[PubMed: 21536716] 
21. Mei S, Quax R, van de Vijver D, Zhu Y, Sloot PM. Increasing risk behaviour can outweigh the 
benefits of antiretroviral drug treatment on the HIV incidence among men-having-sex-with-men in 
Amsterdam. BMC Infect Dis 2011;11:118. [PubMed: 21569307] 
22. Office of National AIDS Policy. National HIV/AIDS strategy for the United States. Washington, 
DC: Office of National AIDS PolicyPublished 7 2010 http://www.whitehouse.gov/sites/default/
files/uploads/NHAS.pdf. Accessed June 8, 2012.
23. Lyles CM, Crepaz N, Herbst JH, Kay LS. Evidence-based HIV behavioral prevention from the 
perspective of the CDC’s HIV/AIDS Prevention Research Synthesis Team. AIDS Educ Prev 
2006;18(4 Suppl A):21–31. [PubMed: 16987086] 
Higa et al. Page 13
AIDS Behav. Author manuscript; available in PMC 2019 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
24. DeLuca JB, Mullins MM, Lyles CM, Crepaz N, Kay L, Thadiparthi S. Developing a 
comprehensive search strategy for evidence-based systematic review. Evid Based Libr Inf Pract 
2011;3(1):3–32.
25. Antoni MH, Cruess DG, Klimas N et al. Stress management and immune system reconstitution in 
symptomatic HIV-infected gay men over time: effects on tranisitional naive T cells 
(CD4+CD45RA+CD29+). Am J Psychiat 2002;159(1):143–144. [PubMed: 11772706] 
26. Carrico AW, Antoni MH, Pereira DB et al. Cognitive behavioral stress management effects on 
mood, social support, and a marker of antiviral immunity are maintained up to 1 year in HIV-
infected gay men. Int J Behav Med 2005;12(4):218–226. [PubMed: 16262540] 
27. Cosio D, Heckman TG, Anderson T, Heckman BD, Garske J, McCarthy J. Telephone-administered 
motivational interviewing to reduce risky sexual behavior in HIV-infected rural persons: a pilot 
randomized clinical trial. Sex Transm Dis 2010;37(3):140–146. [PubMed: 20118830] 
28. Gilbert P, Ciccarone D, Gansky SA et al. Interactive “Video Doctor” counseling reduces drug and 
sexual risk behaviors among HIV-positive patients in diverse outpatient settings. PLoS One 
2008;3(4):e1988. [PubMed: 18431475] 
29. Ironson G, Antoni MH, Schneiderman N et al. Stress management and psychosocial predictors of 
disease course in HIV-1 infection In: Goodkin K, Visser AP, editors. Psychoneuroimmunology: 
Stress, Mental Disorders, and Health.Washington, DC: American Psychiatric Publishing Inc.; 2000 
317–356.
30. Kalichman SC, Rompa D, Cage M et al. Effectiveness of an intervention to reduce HIV 
transmission risks in HIV-positive people. Am J Prev Med 2001;21(2):84–92. [PubMed: 
11457627] 
31. Kelly JA, Murphy DA, Bahr GR et al. Outcome of cognitive-behavioral and support group brief 
therapies for depressed, HIV-infected persons. Am J Psychiatry 1993;150(11):1679–1686. 
[PubMed: 8214177] 
32. Lightfoot M, Tevendale H, Comulada WS, Rotheram-Borus MJ. Who benefited from an 
efficacious intervention for youth living with HIV: a moderator analysis. AIDS Behav 2007;11(1):
61–70. [PubMed: 17009122] 
33. Morin SF, Shade SB, Steward WT et al. A behavioral intervention reduces HIV transmission risk 
by promoting sustained serosorting practices among HIV-infected men who have sex with men. J 
Acquir Immune Defic Syndr 2008;49(5):544–551. [PubMed: 18989221] 
34. Richardson JL, Milam J, McCutchan A et al. Effect of brief safer-sex counseling by medical 
providers to HIV-1 seropositive patients: a multi-clinic assessment. AIDS 2004;18(8):1179–1186. 
[PubMed: 15166533] 
35. Rotheram-Borus MJ, Swendeman D, Comulada WS, Weiss RE, Lee M, Lightfoot M. Prevention 
for substance-using HIV-positive young people: telephone and in-person delivery. J Acquir 
Immune Defic Syndr 2004;37(Suppl 2):S68–S77. [PubMed: 15385902] 
36. Kelly JA, Murphy DA, Sikkema KJ et al. Randomised, controlled, community-level HIV-
prevention intervention for sexual-risk behaviour among homosexual men in US cities. 
Community HIV Prevention Research Collaborative. Lancet 1997;350(9090):1500–1505. 
[PubMed: 9388397] 
37. Goldbaum GM, Johnson W, Wolitski RJ et al. Sexual behavior change among non-gay-identified 
men who have sex with men: response to a community-level intervention. Unpublished 
manuscript.
38. Picciano J, Roffman R, Kalichman S, Rutledge S, Berghuis J. A telephone based brief intervention 
using motivational enhancement to facilitate HIV risk reduction among MSM: a pilot study. AIDS 
and Behavior 2001;5(3):251–262.
39. Carpenter KM, Stoner SA, Mikko AN, Dhanak LP, Parsons JT. Efficacy of a web-based 
intervention to reduce sexual risk in men who have sex with men. AIDS Behav 2010;14(3):549–
557. [PubMed: 19499321] 
40. Rosser BR, Oakes JM, Konstan J et al. Reducing HIV risk behavior of men who have sex with men 
through persuasive computing: results of the Men’s INTernet Study-II. AIDS 2010;24(13):2099–
2107. [PubMed: 20601853] 
Higa et al. Page 14
AIDS Behav. Author manuscript; available in PMC 2019 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
41. Roffman RA, Picciano JF, Ryan R et al. HIV-prevention group counseling delivered by telephone: 
an efficacy trial with gay and bisexual men. AIDS Behav 1997;1(2):137–154.
42. Coleman JD, Lindley LL, Annang L, Saunders RP, Gaddist B. Development of a framework for 
HIV/AIDS prevention programs in African American churches. AIDS Patient Care STDS 
2012;26(2):116–124. [PubMed: 22149766] 
43. Dilley JW, Woods WJ, Sabatino J et al. Changing sexual behavior among gay male repeat testers 
for HIV: a randomized, controlled trial of a single-session intervention. J Acquir Immune Defic 
Syndr 2002;30(2):177–186. [PubMed: 12045680] 
44. Dilley JW, Woods WJ, Loeb L et al. Brief cognitive counseling with HIV testing to reduce sexual 
risk among men who have sex with men: results from a randomized controlled trial using 
paraprofessional counselors. J Acquir Immune Defic Syndr 2007;44(5):569–577. [PubMed: 
17310937] 
45. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV 
infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet 
2004;364(9428):41–50. [PubMed: 15234855] 
46. Mansergh G, Koblin BA, McKirnan DJ et al. An intervention to reduce HIV risk behavior of 
substance-using men who have sex with men: a two-group randomized trial with a nonrandomized 
third group. PLoS Med 2010;7(8):e1000329. [PubMed: 20811491] 
47. Picciano JF, Roffman RA, Kalichman SC, Walker DD. Lowering obstacles to HIV prevention 
services: effects of a brief, telephone-based intervention using motivational enhancement therapy. 
Ann Behav Med 2007;34(2):177–187. [PubMed: 17927556] 
48. Read SJ, Miller LC, Appleby PR et al. Socially optimized learning in a virtual environment: 
reducing risky sexual behavior among men who have sex with men. Health Communication 
Research 2006;32(1):1–34.
49. Velasquez MM, von SK, Johnson DH, Green C, Carbonari JP, Parsons JT. Reducing sexual risk 
behaviors and alcohol use among HIV-positive men who have sex with men: a randomized clinical 
trial. J Consult Clin Psychol 2009;77(4):657–667. [PubMed: 19634959] 
50. Wolitski RJ, Gomez CA, Parsons JT. Effects of a peer-led behavioral intervention to reduce HIV 
transmission and promote serostatus disclosure among HIV-seropositive gay and bisexual men. 
AIDS 2005;19(Suppl 1):S99–S109.
51. Choi KH, Lew S, Vittinghoff E, Catania JA, Barrett DC, Coates TJ. The efficacy of brief group 
counseling in HIV risk reduction among homosexual Asian and Pacific Islander men. AIDS 
1996;10(1):81–87. [PubMed: 8924256] 
52. McKirnan DJ, Tolou-Shams M, Courtenay-Quirk C. The Treatment Advocacy Program: a 
randomized controlled trial of a peer-led safer sex intervention for HIV-infected men who have sex 
with men. J Consult Clin Psychol 2010;78(6):952–963. [PubMed: 20919760] 
53. Wilton L, Herbst JH, Coury-Doniger P et al. Efficacy of an HIV/STI prevention intervention for 
black men who have sex with men: findings from the Many Men, Many Voices (3MV) project. 
AIDS Behav 2009;13(3):532–544. [PubMed: 19267264] 
54. Carballo-Dieguez A, Dolezal C, Leu CS et al. A randomized controlled trial to test an HIV-
prevention intervention for Latino gay and bisexual men: lessons learned. AIDS Care 2005;17(3):
314–328. [PubMed: 15832879] 
55. Coates TJ, McKusick L, Kuno R, Stites DP. Stress reduction training changed number of sexual 
partners but not immune function in men with HIV. Am J Public Health 1989;79(7):885–887. 
[PubMed: 2735479] 
56. Kelly JA, St Lawrence JS, Hood HV, Brasfield TL. Behavioral intervention to reduce AIDS risk 
activities. J Consult Clin Psychol 1989;57(1):60–67. [PubMed: 2925974] 
57. Mausbach BT, Semple SJ, Strathdee SA, Zians J, Patterson TL. Efficacy of a behavioral 
intervention for increasing safer sex behaviors in HIV-positive MSM methamphetamine users: 
results from the EDGE study. Drug Alcohol Depend 2007;87(2–3):249–257. [PubMed: 17182196] 
58. Menza TW, Jameson DR, Hughes JP, Colfax GN, Shoptaw S, Golden MR. Contingency 
management to reduce methamphetamine use and sexual risk among men who have sex with men: 
a randomized controlled trial. BMC Public Health 2010;10:774. [PubMed: 21172026] 
Higa et al. Page 15
AIDS Behav. Author manuscript; available in PMC 2019 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
59. Miller RL. Assisting gay men to maintain safer sex: an evaluation of an AIDS service 
organization’s safer sex maintenance program. AIDS Educ Prev 1995;7(Suppl 5):48–63. [PubMed: 
8664098] 
60. Morgenstern J, Bux DA Jr., Parsons J, Hagman BT, Wainberg M, Irwin T. Randomized trial to 
reduce club drug use and HIV risk behaviors among men who have sex with men. J Consult Clin 
Psychol 2009;77(4):645–656. [PubMed: 19634958] 
61. Peterson JL, Coates TJ, Catania J et al. Evaluation of an HIV risk reduction intervention among 
African-American homosexual and bisexual men. AIDS 1996;10(3):319–325. [PubMed: 8882672] 
62. Roffman RA, Stephen RS, Curtin L et al. Relapse prevention as an interventive model for HIV risk 
reduction in gay and bisexual men. AIDS Educ Prev 1998;10(1):1–18.
63. Rosser BR, Hatfield LA, Miner MH, Ghiselli ME, Lee BR, Welles SL. Effects of a behavioral 
intervention to reduce serodiscordant unsafe sex among HIV positive men who have sex with men: 
the Positive Connections randomized controlled trial study. J Behav Med 2010;33(2):147–158. 
[PubMed: 20101454] 
64. Serovich JM, Reed S, Grafsky EL, Andrist D. An intervention to assist men who have sex with 
men disclose their serostatus to casual sex partners: results from a pilot study. AIDS Educ Prev 
2009;21(3):207–219. [PubMed: 19519236] 
65. Shoptaw S, Reback CJ, Peck JA et al. Behavioral treatment approaches for methamphetamine 
dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug 
Alcohol Depend 2005;78(2):125–134. [PubMed: 15845315] 
66. Stall RD, Paul JP, Barrett DC, Crosby GM, Bein E. An outcome evaluation to measure changes in 
sexual risk-taking among gay men undergoing substance use disorder treatment. J Stud Alcohol 
1999;60(6):837–845. [PubMed: 10606497] 
67. Valdiserri RO, Lyter DW, Leviton LC, Callahan CM, Kingsley LA, Rinaldo CR. AIDS prevention 
in homosexual and bisexual men: results of a randomized trial evaluating two risk reduction 
interventions. AIDS 1989;3(1):21–26. [PubMed: 2496707] 
68. Williams JK, Wyatt GE, Rivkin I, Ramamurthi HC, Li X, Liu H. Risk reduction for HIV-positive 
African American and Latino men with histories of childhood sexual abuse. Arch Sex Behav 
2008;37(5):763–772. [PubMed: 18506611] 
69. Rosser BR, Bockting WO, Rugg DL et al. A randomized controlled intervention trial of a sexual 
health approach to long-term HIV risk reduction for men who have sex with men: effects of the 
intervention on unsafe sexual behavior. AIDS Educ Prev 2002;14(3 Suppl A):59–71. [PubMed: 
12092938] 
70. Stall R, Mills TC, Williamson J et al. Association of co-occurring psychosocial health problems 
and increased vulnerability to HIV/AIDS among urban men who have sex with men. Am J Public 
Health 2003;93(6):939–942. [PubMed: 12773359] 
71. Stall RD, Purcell DW. Intertwining epidemics: a review of research on substance use among men 
who have sex with men and its connection to the AIDS epidemic. AIDS Behav 2000;4(2):181–
192.
72. Ostrow DG, Stall R. Alcohol, tobacco, and drug use among gay and bisexual men In: Wolitski RJ, 
Stall R, Valdiserri RO, editors. Unequal Opportunity: Health Disparities Affecting Gay and 
Bisexual Men In The United States.New York: Oxford University Press; 2008 121–158.
73. Shoptaw S, Reback CJ. Methamphetamine use and infectious disease-related behaviors in men 
who have sex with men: implications for interventions. Addiction 2007;102(Suppl 1):130–135. 
[PubMed: 17493062] 
74. Chesney MA, Koblin BA, Barresi PJ et al. An individually tailored intervention for HIV 
prevention: baseline data from the EXPLORE Study. Am J Public Health 2003;93(6):933–938. 
[PubMed: 12773358] 
75. Jenkins RA. Recruiting substance-using men who have sex with men into HIV prevention research: 
current status and future directions. AIDS Behav 2012;16(6):1411–1419. [PubMed: 22016329] 
76. Hatfield LA, Ghiselli ME, Jacoby SM et al. Methods for recruiting men of color who have sex with 
men in prevention-for-positives interventions. Prev Sci 2010;11(1):56–66. [PubMed: 19731034] 
Higa et al. Page 16
AIDS Behav. Author manuscript; available in PMC 2019 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
77. Parsons JT, Vial AC, Starks TJ, Golub SA. Recruiting Drug Using Men Who Have Sex with Men 
in Behavioral Intervention Trials: A Comparison of Internet and Field-Based Strategies. AIDS 
Behav 2013; 17:688–99. [PubMed: 22684657] 
78. Higa D Gay Men’s Brief Sexual Connections: Settings, Processes, Meanings, and Ethics 
[dissertation]. Seattle, WA: University of Washington; 2008.
79. Mizuno Y, Borkowf C, Millett GA, Bingham T, Ayala G, Stueve A. Homophobia and racism 
experienced by Latino men who have sex with men in the United States: correlates of exposure 
and associations with HIV risk behaviors. AIDS Behav 2012;16(3):724–735. [PubMed: 21630014] 
80. VanDevanter N, Duncan A, Burrell-Piggott T et al. The influence of substance use, social sexual 
environment, psychosocial factors, and partner characteristics on high-risk sexual behavior among 
young Black and Latino men who have sex with men living with HIV: a qualitative study. AIDS 
Patient Care STDS 2011;25(2):113–121. [PubMed: 21235387] 
81. Crepaz N, Lyles CM, Wolitski RJ et al. Do prevention interventions reduce HIV risk behaviours 
among people living with HIV? A meta-analytic review of controlled trials. AIDS 2006;20(2):
143–157. [PubMed: 16511407] 
82. CDC. HIV suveillance in men who have sex with men (MSM). Atlanta, GA http://
www.cdc.gov/hiv/topics/surveillance/resources/slides/msm/index.htm. Accessed June 8, 2012.
83. Bull SS, Lloyd L, Rietmeijer C, McFarlane M. Recruitment and retention of an online sample for 
an HIV prevention intervention targeting men who have sex with men: the Smart Sex Quest 
Project. AIDS Care 2004;16(8):931–943. [PubMed: 15511725] 
84. Rhodes SD, Vissman AT, Stowers J et al. A CBPR partnership increases HIV testing among men 
who have sex with men (MSM): outcome findings from a pilot test of the CyBER/testing internet 
intervention. Health Educ Behav 2011;38(3):311–320. [PubMed: 21393625] 
85. Chiasson MA, Shaw FS, Humberstone M, Hirshfield S, Hartel D. Increased HIV disclosure three 
months after an online video intervention for men who have sex with men (MSM). AIDS Care 
2009;21(9):1081–1089. [PubMed: 20024766] 
86. Reback CJ, Ling D, Shoptaw S, Rohde J. Developing a text messaging risk reduction intervention 
for methamphetamine-using MSM: research note. Open AIDS J 2010;4:116–122. [PubMed: 
20657827] 
87. Bowen AM, Horvath K, Williams ML. A randomized control trial of Internet-delivered HIV 
prevention targeting rural MSM. Health Educ Res 2007;22(1):120–127. [PubMed: 16849391] 
88. El-Bassel N, Gilbert L, Witte S, Wu E, Hunt T, Remien RH. Couple-based HIV prevention in the 
United States: advantages, gaps, and future directions. J Acquir Immune Defic Syndr 
2010;55(Suppl 2):S98–S101. [PubMed: 21406997] 
89. Sullivan PS, Salazar L, Buchbinder S, Sanchez TH. Estimating the proportion of HIV 
transmissions from main sex partners among men who have sex with men in five US cities. AIDS 
2009;23(9):1153–1162. [PubMed: 19417579] 
90. Wu E, El-Bassel N, McVinney LD et al. Feasibility and promise of a couple-based HIV/STI 
preventive intervention for methamphetamine-using, black men who have sex with men. AIDS 
Behav 2011;15(8):1745–1754. [PubMed: 21766193] 
91. Elford J, Hart G. If HIV prevention works, why are rates of high-risk sexual behavior increasing 
among MSM? AIDS Educ Prev 2003;15(4):294–308. [PubMed: 14516015] 
92. Sullivan PS, Wolitski RJ. HIV infection among gay and bisexual men In: Sullivan PS, Wolitski RJ, 
editors. Unequal Opportunity: Health Disparities Affecting Gay and Bisexual Men in the United 
States.New York: Oxford Univeristy Press; 2008 221–247.
93. Chen HT. The bottom-up approach to integrative validity: a new perspective for program 
evaluation. Eval Program Plann 2010;33(3):205–214. [PubMed: 19931908] 
Higa et al. Page 17
AIDS Behav. Author manuscript; available in PMC 2019 August 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Flow chart of search
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